Efficacy of spironolactone in adult acne in polycystic ovary syndrome patients an original research

Introduction: This prospective clinical trial was designed to assess the effects of a long-term therapy with spironolactone, with and without dietary-induced weight-loss, on clinical features, lipid profile, and insulin levels in women with polycystic ovary syndrome (PCOS). Materials and Methods: Tw...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Neha Rani, Prashant Kumar, Anup Kumar Mishra, Bala Yadu Vamsi Sankuratri, Sanjana Sethi, Kalyani Gelada, Heena Tiwari
Formato:	article
Lenguaje:	EN
Publicado:	Wolters Kluwer Medknow Publications 2021
Materias:	efficacy polycystic ovary syndrome spironolactone Pharmacy and materia medica RS1-441 Analytical chemistry QD71-142
Acceso en línea:	https://doaj.org/article/de04ff83bddb446d937dea16f60e1870
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:de04ff83bddb446d937dea16f60e1870
record_format	dspace
spelling	oai:doaj.org-article:de04ff83bddb446d937dea16f60e18702021-11-19T12:15:53ZEfficacy of spironolactone in adult acne in polycystic ovary syndrome patients an original research0975-740610.4103/jpbs.jpbs_391_21https://doaj.org/article/de04ff83bddb446d937dea16f60e18702021-01-01T00:00:00Zhttp://www.jpbsonline.org/article.asp?issn=0975-7406;year=2021;volume=13;issue=6;spage=1659;epage=1663;aulast=Ranihttps://doaj.org/toc/0975-7406Introduction: This prospective clinical trial was designed to assess the effects of a long-term therapy with spironolactone, with and without dietary-induced weight-loss, on clinical features, lipid profile, and insulin levels in women with polycystic ovary syndrome (PCOS). Materials and Methods: Twenty-five patients (range of age 16–32 year; 13 lean and 12 overweight) fulfilling formal diagnostic criteria for PCOS (oligomenorrhea and/or amenorrhea, biochemical and/or clinical evidence of hyperadrogenism) were studied at baseline and then received oral spironolactone (100 mg/die) for 12 months; association with lifestyle modifications was recommended to all overweight patients. Clinical, endocrine, and metabolic parameters (oral glucose tolerance test [OGTT], lipid profile) were measured at baseline and at the end of the antiandrogen treatment. Results: The therapy was associated with a significant average decline of triglycerides in overweight subjects and with increased high-density lipoprotein-cholesterol levels in lean patients. The insulin levels at 60 min during OGTT, homeostasis model assessment-insulin resistance and area under curve of insulin were significantly lowered in overweight women after 12 months of spironolactone and weight loss and no negative changes in insulin secretion and sensitivity were observed in PCOS women after pharmacological treatment alone. Conclusion: The efficacy of spironolactone on the androgenic clinical aspects of PCOS has been confirmed in this study. Furthermore, our data show that long-term treatment with spironolactone exerts no negative effects on lipoprotein profile and glucose metabolism; more relevant beneficial effects on glucose and lipid metabolism were observed when the antiandrogen was associated with weight loss in overweight PCOS women.Neha RaniPrashant KumarAnup Kumar MishraBala Yadu Vamsi SankuratriSanjana SethiKalyani GeladaHeena TiwariWolters Kluwer Medknow Publicationsarticleefficacypolycystic ovary syndromespironolactonePharmacy and materia medicaRS1-441Analytical chemistryQD71-142ENJournal of Pharmacy and Bioallied Sciences, Vol 13, Iss 6, Pp 1659-1663 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	efficacy polycystic ovary syndrome spironolactone Pharmacy and materia medica RS1-441 Analytical chemistry QD71-142
spellingShingle	efficacy polycystic ovary syndrome spironolactone Pharmacy and materia medica RS1-441 Analytical chemistry QD71-142 Neha Rani Prashant Kumar Anup Kumar Mishra Bala Yadu Vamsi Sankuratri Sanjana Sethi Kalyani Gelada Heena Tiwari Efficacy of spironolactone in adult acne in polycystic ovary syndrome patients an original research
description	Introduction: This prospective clinical trial was designed to assess the effects of a long-term therapy with spironolactone, with and without dietary-induced weight-loss, on clinical features, lipid profile, and insulin levels in women with polycystic ovary syndrome (PCOS). Materials and Methods: Twenty-five patients (range of age 16–32 year; 13 lean and 12 overweight) fulfilling formal diagnostic criteria for PCOS (oligomenorrhea and/or amenorrhea, biochemical and/or clinical evidence of hyperadrogenism) were studied at baseline and then received oral spironolactone (100 mg/die) for 12 months; association with lifestyle modifications was recommended to all overweight patients. Clinical, endocrine, and metabolic parameters (oral glucose tolerance test [OGTT], lipid profile) were measured at baseline and at the end of the antiandrogen treatment. Results: The therapy was associated with a significant average decline of triglycerides in overweight subjects and with increased high-density lipoprotein-cholesterol levels in lean patients. The insulin levels at 60 min during OGTT, homeostasis model assessment-insulin resistance and area under curve of insulin were significantly lowered in overweight women after 12 months of spironolactone and weight loss and no negative changes in insulin secretion and sensitivity were observed in PCOS women after pharmacological treatment alone. Conclusion: The efficacy of spironolactone on the androgenic clinical aspects of PCOS has been confirmed in this study. Furthermore, our data show that long-term treatment with spironolactone exerts no negative effects on lipoprotein profile and glucose metabolism; more relevant beneficial effects on glucose and lipid metabolism were observed when the antiandrogen was associated with weight loss in overweight PCOS women.
format	article
author	Neha Rani Prashant Kumar Anup Kumar Mishra Bala Yadu Vamsi Sankuratri Sanjana Sethi Kalyani Gelada Heena Tiwari
author_facet	Neha Rani Prashant Kumar Anup Kumar Mishra Bala Yadu Vamsi Sankuratri Sanjana Sethi Kalyani Gelada Heena Tiwari
author_sort	Neha Rani
title	Efficacy of spironolactone in adult acne in polycystic ovary syndrome patients an original research
title_short	Efficacy of spironolactone in adult acne in polycystic ovary syndrome patients an original research
title_full	Efficacy of spironolactone in adult acne in polycystic ovary syndrome patients an original research
title_fullStr	Efficacy of spironolactone in adult acne in polycystic ovary syndrome patients an original research
title_full_unstemmed	Efficacy of spironolactone in adult acne in polycystic ovary syndrome patients an original research
title_sort	efficacy of spironolactone in adult acne in polycystic ovary syndrome patients an original research
publisher	Wolters Kluwer Medknow Publications
publishDate	2021
url	https://doaj.org/article/de04ff83bddb446d937dea16f60e1870
work_keys_str_mv	AT neharani efficacyofspironolactoneinadultacneinpolycysticovarysyndromepatientsanoriginalresearch AT prashantkumar efficacyofspironolactoneinadultacneinpolycysticovarysyndromepatientsanoriginalresearch AT anupkumarmishra efficacyofspironolactoneinadultacneinpolycysticovarysyndromepatientsanoriginalresearch AT balayaduvamsisankuratri efficacyofspironolactoneinadultacneinpolycysticovarysyndromepatientsanoriginalresearch AT sanjanasethi efficacyofspironolactoneinadultacneinpolycysticovarysyndromepatientsanoriginalresearch AT kalyanigelada efficacyofspironolactoneinadultacneinpolycysticovarysyndromepatientsanoriginalresearch AT heenatiwari efficacyofspironolactoneinadultacneinpolycysticovarysyndromepatientsanoriginalresearch
_version_	1718420163089399808

Efficacy of spironolactone in adult acne in polycystic ovary syndrome patients an original research

Ejemplares similares